×
About 119,600 results

Functional characterization and clinical significance of super-enhancers in lung adenoc...
https://doi.org/10.1002/mc.23419
Molecular Carcinogenesis; Jiang X, Qin N et. al.

May 22nd, 2022 - Super-enhancers (SEs) are important transcriptional regulators in tumorigenesis; however, the functional characterization and clinical significance of SEs in lung adenocarcinoma (LUAD) remain unclear. By using H3K27ac ChIP-seq data of two LUAD cell lines and eight lung tissues, we detected 1045 cancer-specific and 5032 normal-specific SEs. Compared to normal-specific SEs, cancer-specific SEs ha...

Revisiting laminin and extracellular matrix remodeling in metastatic squamous cell carc...
https://doi.org/10.1002/mc.23417
Molecular Carcinogenesis; Aleman JD, Young CD et. al.

May 22nd, 2022 - Patients with squamous cell carcinoma (SCC) have significantly lower survival upon the development of distant metastases. The extracellular matrix (ECM) is a consistent yet dynamic influence on the metastatic capacity of SCCs. The ECM encompasses a milieu of structural proteins, signaling molecules, and enzymes. Just over 40 years ago, the fibrous ECM glycoprotein laminin was identified. Roughl...

BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancin...
https://doi.org/10.1007/s11912-022-01286-0 10.1038/s41375-020-01072-6 10.1182/blood-2015-03-635326 10.1038/s41375-018-0023-2 10.1186/s13045-021-01049-7 10.1182/bloodadvances.2018013060 10.1182/blood-2013-06-507947 10.1186/s13045-016-0250-9 10.1021/acs.jmedchem.9b00687 10.1016/S0140-6736(17)33108-2 10.1056/NEJMoa1914347 10.1111/bjh.15567 10.3389/fonc.2020.591577 10.1097/MOH.0000000000000548 10.1002/ijc.33212 10.1182/blood-2015-11-679134 10.1111/cas.14915 10.1182/blood.2019002936 10.1182/bloodadvances.2020003391 10.1097/CJI.0000000000000307 10.1186/s13045-020-00914-1 10.1016/S0140-6736(15)00667-4 10.1182/blood-2020-134824 10.1016/S0140-6736(21)00224-5 10.1182/blood-2015-05-647834 10.3389/fonc.2021.760405 10.3389/fcell.2021.630942 10.3389/fonc.2021.668162 10.1182/blood.2020006449 10.1111/jth.13651 10.1038/leu.2014.247 10.1200/JCO.21.00693 10.1016/j.jacc.2019.07.056 10.1111/bjh.14870 10.21037/apm.2019.08.05 10.1182/blood.2020006844 10.1016/j.ccell.2017.04.012 10.1182/blood-2017-11-818286 10.1182/blood-2019-125488 10.1182/blood-2019-127674 10.1038/s41467-021-22872-z 10.3389/fimmu.2021.689472 10.1038/s41419-017-0157-6 10.1002/ajh.25418 10.3389/fonc.2020.00849 10.1016/j.bbmt.2019.08.015 10.1182/blood-2020-136158 10.1182/blood-2021-153277 10.1182/blood-2021-148626 10.1200/JCO.2017.72.8519 10.1182/blood-2020-136831 10.1182/blood-2021-146941 10.1016/j.bbmt.2018.12.758 10.1136/esmoopen-2020-000746 10.1038/s41571-019-0297-y 10.1182/blood-2021-150431 10.1182/blood-2021-150592 10.1158/2159-8290.CD-18-0442 10.3324/haematol.2020.267914 10.1182/blood-2021-151073 10.1007/s11864-021-00907-3 10.3324/haematol.2018.198812 10.1186/s13045-021-01188-x 10.1016/j.leukres.2020.106432 10.1111/imcb.12254
Current Oncology Reports; Munoz JL, Wang Y et. al.

May 22nd, 2022 - This review focuses on the feasibility of combining Bruton's tyrosine kinase (BTK) inhibitors (BTKis) with chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL). Potential scenarios for combination treatment with these agents are presented. BTKis and CAR T-cell therapy have revolutionized the treatment paradigm for R/R MCL. Ibrut...

Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and ...
https://doi.org/10.1038/s41416-022-01839-x 10.1038/nrgastro.2011.20 10.1053/j.gastro.2013.10.013 10.1038/nrgastro.2016.51 10.1038/s41575-020-0310-z 10.1016/S0140-6736(13)61903-0 10.1056/NEJMoa1910836 10.1056/NEJMoa1606774 10.1001/jamaoncol.2020.0930 10.1001/jamaoncol.2020.2814 10.1016/j.cell.2014.12.021 10.1038/nm.4438 10.1016/j.stem.2016.04.003 10.1038/s41467-018-05190-9 10.1016/j.cell.2017.11.010 10.1016/j.cell.2015.03.053 10.1016/j.stem.2018.09.016 10.1016/j.canlet.2021.06.007 10.1186/s12885-018-4238-4 10.1080/2162402X.2020.1845424 10.1016/j.cell.2018.07.009 10.1016/j.celrep.2019.03.088 10.1016/j.celrep.2018.07.001 10.1053/j.gastro.2017.10.043 10.1053/j.gastro.2017.06.017 10.1158/2326-6066.CIR-21-0058 10.1038/nprot.2008.211 10.1093/nar/gkn923 10.1016/S0973-6883(11)60110-2 10.1007/s10620-014-3472-0 10.1002/hep.28493 10.1084/jem.190.12.1879 10.1002/jcp.27782 10.1038/s41577-018-0044-0 10.3389/fonc.2019.00989
British Journal of Cancer; Zhou G, Lieshout R et. al.

May 22nd, 2022 - Immunotherapy with immune checkpoint inhibitors (ICIs) is being explored to improve cholangiocarcinoma (CCA) therapy. However, it remains difficult to predict which ICI will be effective for individual patients. Therefore, the aim of this study is to develop a co-culture method with patient-derived CCA organoids and immune cells, which could represent anti-cancer immunity in vitro. CCA organoid...

Epigenetic Regulation of IFI44L Expression in Monocytes Affects the Functions of Monocy...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9113863
Journal of Immunology Research; Luo S, Wu R et. al.

May 21st, 2022 - Interferon-inducible 44 like (IFI44L) is a newly discovered interferon-induced gene and has been reported to overexpress in systemic lupus erythematosus (SLE). However, little is known about the mechanism and function of IFI44L overexpression in SLE. In this study, we aimed to investigate the epigenetic mechanism of IFI44L overexpression in SLE monocyte and its potential functions contributing ...

Distribution and frequency of tyrosine kinase inhibitor-associated long-term complicati...
https://doi.org/10.1002/pbc.29786
Pediatric Blood & Cancer; Dong EE, Bruno MA et. al.

May 21st, 2022 - Tyrosine kinase inhibitors (TKIs) improve outcomes for pediatric malignancies characterized by specific gene rearrangements and mutations; however, little is known about the long-term impact of TKI exposure. Our objective was to assess the incidence and type of late-onset TKI-related toxicities in children with chronic myeloid leukemia (CML). We reviewed medical records from patients diagnosed ...

A Comprehensive Review of PCSK9 Inhibitors.
https://doi.org/10.1177/10742484221100107
Journal of Cardiovascular Pharmacology and Therapeutics; Coppinger C, Movahed MR et. al.

May 21st, 2022 - Cardiovascular disease (CVD) is the leading cause of death in the United States and worldwide. A major risk factor for this condition is increased serum low-density lipoprotein cholesterol (LDL-C) levels for which statins have been successful in reducing serum LDL-C to healthy concentrations. However, patients who are statin intolerant or those who do not achieve their treatment goals while on ...

MiR-26b-5p in small extracellular vesicles derived from dying tumor cells after irradia...
https://doi.org/10.1016/j.canlet.2022.215746
Cancer Letters; Yin X, Tian M et. al.

May 21st, 2022 - Radiation therapy is effective in achieving local control in esophageal squamous cell carcinoma; however, changes in the tumor microenvironment induced by radiation can also promote metastasis. Dying tumor cells play vital roles in promoting the survival of living tumor cells; however, few studies have investigated the effects of dying tumor cells on the tumor microenvironment. Since myeloid-de...

A randomized controlled trial of Everolimus for neurocognitive symptoms in PTEN hamarto...
https://doi.org/10.1093/hmg/ddac111
Human Molecular Genetics; Srivastava S, Jo B et. al.

May 21st, 2022 - PTEN hamartoma tumor syndrome (PHTS) is a complex neurodevelopmental disorder characterized by mTOR (mechanistic target of rapamycin) overactivity. Limited data suggest that mTOR inhibitors may be therapeutic. No placebo-controlled studies have examined mTOR inhibition on cognition and behavior in humans with PHTS with/without autism. We conducted a 6-month phase II, randomized, double-blinded,...

Tumor-associated macrophages regulate the function of cytotoxic T lymphocyte through PD...
https://doi.org/10.1002/cam4.4814
Cancer Medicine; Zhang J, Liu Z et. al.

May 21st, 2022 - Tumor-associated macrophages (TAMs) are originated from circulating mononuclear cells in peripheral blood. They result from the recruitment of tumor cells and are a vital constituent of the tumor microenvironment. TAMs may be involved in the immunological escape of vicious clonal plasma cells (PC) in the bone marrow (BM) of sufferers with myeloma. From March 2020 to January 2021, 28 healthy con...

Role of Lysine Specific Demethylase 1 and Its Small Molecule Inhibitors in Glioblastoma...
https://doi.org/10.2174/1871520622666220421092414
Anti-cancer Agents in Medicinal Chemistry; Mitra R, Ayyannan SR

May 21st, 2022 - Glioblastoma multiforme (GBM) is among the most critical and aggressive carcinomas of CNS, characterised by poor prognosis, low survival rate and difficult clinical correlations. Current treatment opportunities have proved to be insufficient due to high chemoresistance, and relapse of the disease with enhanced malignancy. Molecular diagnostics and epigenetic profiling of GBM have discovered sev...

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
https://clinicaltrials.gov/ct2/show/NCT04915183

May 20th, 2022 - Study Description: Individuals undergoing cisplatin-based chemoradiation therapy are at risk for developing significant, permanent hearing loss. The cholesterol-lowering drug atorvastatin has the potential to reduce the incidence and severity of hearing loss, as evidenced by our preclinical data in mice and our retrospective data in humans.Here we will compare hearing changes between subjects o...

Assessing PA-824 for Tuberculosis (the APT Trial)
https://clinicaltrials.gov/ct2/show/NCT02256696

May 20th, 2022 - Phase IIB, 12-week, open-label, single-site, randomized clinical trial with three treatment groups. Patients with drug-sensitive TB will all receive once daily isoniazid and pyrazinamide for 8 weeks followed by 4 weeks of daily isoniazid. In addition, Arm 1 participants will receive PA-824 200 mg daily and rifampin 600 mg daily for 12 weeks. Arm 2 participants will receive PA-824 200 mg daily a...

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumati...
https://clinicaltrials.gov/ct2/show/NCT04908189

May 20th, 2022 - The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
https://clinicaltrials.gov/ct2/show/NCT00044304

May 20th, 2022 - This study will evaluate the safety and effectiveness of imatinib mesylate in reducing the number of eosinophils (a type of white blood cell) in patients with hypereosinophilic syndrome (HES). Patients with HES have elevated counts of eosinophils in the blood and body tissues, which can cause damage to these tissues. Although HES can involve any tissues, the heart, nerves, and skin are most oft...

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
https://clinicaltrials.gov/ct2/show/NCT03805932

May 20th, 2022 - Background: Hairy cell leukemia (HCL) is an indolent CD22+ B-cell leukemia comprising 2% of all leukemias, or approximately 1200 of the 62,130 new cases of leukemia/year in the US. HCL variant (HCLv), also CD22+, is 10-20% as common as HCL, but more common in the relapsed/refractory population due to its poor prognosis and response to standard purine analog chemotherapy. HCLv cells are CD25-neg...

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT03366116

May 20th, 2022 - Background: Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. Two DNA hypomethylating nucleosides, 5-azacytidine (azacytidine) and 5-aza-2'-deoxycytidine (decitabine) have been approved by the FDA for the treatment ...

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
https://clinicaltrials.gov/ct2/show/NCT03377491

May 20th, 2022 - PAST PRE-CLINICAL AND CLINICAL EXPERIENCE: The effect of the electric fields (TTFields, TTF) has demonstrated significant activity in in vitro and in vivo pancreatic adenocarcinoma pre-clinical models both as a single modality treatment and in combination with chemotherapies. TTFields have been demonstrated to act synergistically with taxanes and have been shown to be additive when combined wit...

HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
https://clinicaltrials.gov/ct2/show/NCT02437110

May 20th, 2022 - Objective: In this Phase I, proof-of-concept study, we aim to determine whether an antiretroviral regimen approved to treat human immunodeficiency virus (HIV) infection would also suppress levels of Human Endogenous Retrovirus-K (HERV-K) found to be activated in a subset of patients with amyotrophic lateral sclerosis (ALS). We propose to measure the of blood levels of HERV-K by quantitative PCR...

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
https://clinicaltrials.gov/ct2/show/NCT03258567

May 20th, 2022 - BACKGROUND: Epstein-Barr virus (EBV) is a chronic viral infection associated with a heterogeneous group of lymphoproliferative disorders (LPD) and non-Hodgkin lymphomas (NHL). The shared pathobiology of EBV-positive LPDs and NHLs includes a defect in host mechanisms of immune tolerance and immunosurveillance. Programmed death-1 (PD-1) is a surface protein present on T cells, B cells, and macrop...